Last updated 4 days ago
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
380 patients around the world
Available in Brazil, Puerto Rico, United States
Hoffmann-La Roche
1Research sites
380Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment.Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible.MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria.Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide.Participants must have measurable disease during screening.
- Known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan).Plasma cell leukemia or circulating plasma cell count exceeding 500 cells/liter (L) or 5% of the peripheral blood white cells.GI disease that might significantly alter absorption of oral drugs.Participants must not have any ongoing CNS disease or non-secretory myeloma.
Sites
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
Recruiting
StudyCEVOLUTION
SponsorHoffmann-La Roche
Study typeInterventional
Conditions
Multiple myeloma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07555938
